ARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On June 6, 2022, Arbutus Biopharma Corporation ("Arbutus") and Vaccitech plc ("Vaccitech") issued a press release announcing the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus' RNAi therapeutic candidate, AB-729, in combination with Vaccitech's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number    Description

  99.1              Press release dated June 6, 2022
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses